logo

For the Inventor, By the Inventor

Basel, Switzerland

Nbe-therapeutics Ag


USPTO Granted Patents = 15



Trademarks = 1

Forward Citations = 42

Loading Chart...
Loading Chart...

7 inventors (with patents filed for the assignee):

goldMedal Ulf Grawunder (15 out of 22 patents)

silverMedal Roger Renzo Beerli (15 out of 19 patents)

bronzeMedal Lorenz Waldmeier (5 out of 5 patents)

4.  Christoph Rader (2 out of 26 patents)

5.  Haiyong Peng (2 out of 4 patents)

6.  Remy Gebleux (2 out of 2 patents)

7.  Ina Hellmann (2 out of 2 patents)

8.  Chasper Puorger (0 patent)

9.  Salvatore Di Girolamo (0 patent)

10.  Georg Lipps (0 patent)


15 patents:

1. 12275789 - Human antibodies binding to ROR2 (2025-04-14),
2. 12121527 - Anthracycline-based antibody drug conjugates having high in vivo tolerability (2024-10-22),
3. 11986535 - Method of producing an immunoligand/payload conjugate (2024-05-21),
4. 11845793 - Anti-ROR1 antibodies (2023-12-19),
5. 11833120 - Binding protein drug conjugates comprising anthracycline derivatives (2023-12-05),
6. 11447546 - Human antibodies binding to ROR2 (2022-09-20),
7. 11364301 - Method of producing an immunoligand/payload conjugate (2022-06-21),
8. 11242388 - ROR1 antibody compositions and related methods (2022-02-08),
9. 10960083 - Binding protein drug conjugates comprising anthracycline derivatives (2021-03-30),
10. 10864277 - Method of producing an immunoligand/payload conjugate (2020-12-15),
11. 10758556 - Anthracycline-based antibody drug conjugates having high in vivo tolerability (2020-09-01),
12. 10618959 - ROR1 antibody compositions and related methods (2020-04-14),
13. 10517959 - Binding protein drug conjugates comprising anthracycline derivatives (2019-12-31),
14. 10188745 - Binding protein drug conjugates comprising anthracycline derivatives (2019-01-29),
15. 9872923 - Method of producing an immunoligand/payload conjugate (2018-01-23),
NBE Therapeutics AG is a biotechnology company that develops next-generation antibody-drug conjugates (ADCs) for cancer therapy. Their patented platform enables highly potent ADCs with improved efficacy and safety profiles. NBE Therapeutics aims to revolutionize cancer treatment by delivering innovative therapies that target specific cancer cells while minimizing side effects on healthy tissues.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

15 Patents

#30 in Basel

#778 in Switzerland

#38,727 in the World

...
Basel, Switzerland

Nbe-therapeutics Ag

Forward Citations = 42

7 inventors:

goldMedal Ulf Grawunder (15 out of 22 patents)

silverMedal Roger Renzo Beerli (15 out of 19 patents)

bronzeMedal Lorenz Waldmeier (5 out of 5 patents)

4.  Christoph Rader (2 out of 26 patents)

5.  Haiyong Peng (2 out of 4 patents)

Please report any incorrect information to support@idiyas.com
Loading…